The FDA recommends that companies use overall survival as a primary endpoint for clinical trials where feasible. The new ...

Regulations aiming to lower the cost of vital medicines will instead end up restricting access and disincentivizing R&D.

With its structural changes, CSL expects to generate $500 to $550 million in annualized savings over the next three years.

The CDC no longer recommends COVID-19 vaccines for healthy children and healthy pregnant women, a position that has been opposed by leading medical societies.